Common Biomarkers and Pathogenesis of Inflammatory Bowel Disease and Breast Cancer: Mendelian Randomization and Multi-Omics Studies
This study provides genetic evidence supporting IBD as a risk factor for breast cancer and highlights THBS3 as a key shared biomarker. THBS3 may promote breast cancer progression through immune regulation, ECM remodeling, and drug resistance mechanisms, suggesting its potential as a therapeutic target. These findings support enhanced breast cancer screening in IBD patients.
Authors
- Faping You
- Daqing Zhang (ORCID: https://orcid.org/0000-0002-6608-1267)
- Qingze Xue
- Haitao Tang (ORCID: https://orcid.org/0000-0001-7531-0458)
- Bin Xu (ORCID: https://orcid.org/0000-0002-0499-0430)
- Yongjun Guan (ORCID: https://orcid.org/0000-0003-1148-4373)
- Xiaoqiang Li (ORCID: https://orcid.org/0000-0002-4191-8243)
Institutions
- National Clinical Research Center for Digestive Diseases (CN)
- Shengli Oilfield Central Hospital (CN)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/bctt.s546371
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00